m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT02193
 [1], [2]
DNA methylation DNMT3A PTPN13 Indirect Inhibition m6A modification TK1 TK1 IGF2BP1 : m6A sites
m6A Modification:
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) READER
 Regulator Info 
m6A Target Thymidine kinase, cytosolic (TK1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type DNA methylation (DNAMeth)
Epigenetic Regulator Cysteine methyltransferase DNMT3A (DNMT3A) WRITER View Details
Regulated Target Protein tyrosine phosphatase non-receptor type 13 (PTPN13) View Details
Crosstalk Relationship DNA methylation  →  m6A Inhibition
Crosstalk Mechanism DNA methylation indirectly regulates m6A modification through downstream signaling pathways
Crosstalk Summary We identified Protein tyrosine phosphatase non-receptor type 13 (PTPN13) expression by upregulating the expression of DNMT3A and IGF2BP1 as a novel PTPN13-interacting gene and demonstrated that PTPN13 influences c-Myc expression by directly and competitively binding to IGF2BP1 to decrease the intracellular concentration of functional IGF2BP1. Overexpressing PTPN13 promoted c-Myc mRNA degradation independent of the protein tyrosine phosphatase (PTP) activity of PTPN13. Importantly, we discovered that the PTPN13-IGF2BP1-c-Myc axis was important for cancer cell growth through promoting metabolic reprogramming. In contrast to the mRNA-decay-promoting function of YTH domain-containing family protein 2, IGF2BPs promote the stability and storage of their target mRNAs (for example, MYC) in an m6A-dependent manner under normal and stress conditions and therefore affect gene expression output. Four representative high confidence targets, including MYC, FSCN1, Thymidine kinase, cytosolic (TK1), and MARCKSL1, exhibit strong binding with IGF2BPs around their m6A motifs in control cells. Knocking down of each individual IGF2BPs in Hela (cervical cancer) and HepG2 (liver cancer) cells significantly repressed MYC expression.
Responsed Disease Liver cancer ICD-11: 2C12
 Disease Info 
Cell Process RNA decay
In-vitro Model
 Hep-G2/2.2.15 Hepatoblastoma Homo sapiens CVCL_L855
Huh-7 Adult hepatocellular carcinoma Homo sapiens CVCL_0336
L-02 Endocervical adenocarcinoma Homo sapiens CVCL_6926
Hep-G2 Hepatoblastoma Homo sapiens CVCL_0027
SK-HEP-1 Liver and intrahepatic bile duct epithelial neoplasm Homo sapiens CVCL_0525
MHCC97-L Adult hepatocellular carcinoma Homo sapiens CVCL_4973
LM3 Malignant neoplasms Mus musculus CVCL_D269
MHCC97-H Adult hepatocellular carcinoma Homo sapiens CVCL_4972
L-02 Endocervical adenocarcinoma Homo sapiens CVCL_6926
SMMC-7721 Endocervical adenocarcinoma Homo sapiens CVCL_0534
PLC/PRF/5 Adult hepatocellular carcinoma Homo sapiens CVCL_0485
Hep 3B2.1-7 Childhood hepatocellular carcinoma Homo sapiens CVCL_0326
In-vivo Model A total of 3 x 106 cells were suspended and mixed with Matrigel (BD Biosciences, Bedford, MA, USA) at a 1:3 volume ratio in 100 μ L of serum-free DMEM and injected subcutaneously into mice. Tumor volumes were measured every 3 days using a caliper and calculated using the standard formula V = shortest diameter2× longest diameter/2. The mice were euthanized when animals exhibited either 30 days after subcutaneous injection or large tumors (volume > 1500 mm3) or obvious signs of discomfort. The tumor was removed, photographed and weighed before being fixed in 10% buffered formalin and analyzed by hematoxylin and eosin (H&E) staining and IHC.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Cysteine methyltransferase DNMT3A (DNMT3A) 8 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PMID27376512-Compound-Figure3CN Patented [3]
MOA Inhibitor
Activity EC50 = 1100 nM
External Link
CID: 117968550
TTD: D02VTV
 Compound Name PMID27376512-Compound-Figure3CG Patented [3]
MOA Inhibitor
Activity EC50 = 2400 nM
External Link
CID: 117967861
TTD: D03LZO
 Compound Name PMID27376512-Compound-Figure3CM Patented [3]
MOA Inhibitor
Activity EC50 = 1100 nM
External Link
CID: 117976053
TTD: D0F8AB
 Compound Name PMID27376512-Compound-Figure2aExample1 Patented [3]
MOA Inhibitor
Activity IC50 = 3000 nM
External Link
CID: 71521835
TTD: D01LUJ
 Compound Name PMID27376512-Compound-MTC-424 Patented [3]
MOA Inhibitor
Activity IC50 = 1940 nM
External Link
TTD: D02WRM
 Compound Name PMID27376512-Compound-MTC-427 Patented [3]
MOA Inhibitor
Activity IC50 = 295 nM
External Link
TTD: D0HA0J
 Compound Name PMID27376512-Compound-MTC-422 Patented [3]
MOA Inhibitor
Activity IC50 = 1430 nM
External Link
TTD: D0QY0N
 Compound Name PMID27376512-Compound-MTC-423 Patented [3]
MOA Inhibitor
Activity IC50 = 363 nM
External Link
TTD: D0W9VZ
Protein tyrosine phosphatase non-receptor type 13 (PTPN13) 2 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name US9217012, 10 Patented [4]
Synonyms
SCHEMBL19222783; CHEMBL3969776; BDBM199180
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 122198705
TTD: D0CW5D
 Compound Name ISIS 18473 Investigative [5]
External Link
TTD: D09VLX
Thymidine kinase, cytosolic (TK1) 39 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name DEOXYCYTIDINE Approved [6]
Synonyms
Cytosine deoxyribonucleoside; 2'-dC; bmse000323; ACMC-209rv6; CYTIDINE, 2'-DEOXY-; Cytosine deoxy nucleoside hydrochloride; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Desoxycytidine; 4-amino-1-(2-deoxypentofuranosyl)pyrimidin-2(1H)-one; 4-amino-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; 3h-deoxycytidine; 4-amino-1-(4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 40093-94-5; AC1L19OG; TimTec1_003892; NCIOpen2_004589; Oprea1_817993
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 13711
TTD: D0RX7Z
DrugBank: DB02594
 Compound Name Penciclovir Approved [7]
Synonyms
39809-25-1; Denavir; Penciclovirum; Vectavir; Penciclovirum [INN-Latin]; Pencyclovir; BRL-39123; BRL 39123; Penciclovir [USAN:INN:BAN]; Penciceovir; UNII-359HUE8FJC; CCRIS 9213; PE2
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 135398748
TTD: D07BYK
DrugBank: DB00299
 Compound Name TK-DLI Preregistration [8]
Synonyms
TBI-0301; Herpes simplex thymidine kinase suicide gene therapy, MolMed/Takara Bio; HSV thymidine kinase gene therapy (GvH, retroviral vector), Istituto Scientifico H San Raffaele; HSV-TK suicide gene therapy, MolMed/Takara Bio; TK cell therapy (haploidentical haematopoietic stem cell transplantation), MolMed/Takara Bio; HSV-TK gene therapy (haematological malignancies), MolMed/Takara Bio; TK-DLI, San Raffaele/MolMed/Takara Bio; TK gene/cell therapy (bone marrow transplantation-associated GvHD prevention), MolMed/Takara Bio; TK-expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed; Thymidine kinase expressing donor T-cells (bone marrow transplantation-associated GvHD prevention), San Raffaele/MolMed/Takara
    Click to Show/Hide
MOA Modulator
External Link
TTD: D08AMJ
 Compound Name FV-100 Phase 3 [9]
Synonyms
CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 71587897
TTD: D04QPD
 Compound Name Radiosensitizer gene therapy Phase 3 [10]
Synonyms
Radiosensitizer gene therapy (prostate cancer)
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0X4NF
 Compound Name RP101 Phase 2/3 [11]
Synonyms
SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 100 nM
External Link
CID: 446727
TTD: D0Z9LP
DrugBank: DB03312
 Compound Name HQK-1004 Phase 2 [12]
Synonyms
Arginine butyrate; VX-105; VX-105); Arginine butyrate (hematological malignancies), HemaQuest
    Click to Show/Hide
MOA Modulator
External Link
CID: 23622962
TTD: D05RRA
 Compound Name Ad-OC-hsvTK/valacyclovir Phase 1 [13]
Synonyms
Ad-OC-hsvTK; Gene therapy (prostate cancer), Winship Cancer Institute; Adenovirus osteocalcin-promoter-driven HSV thymidine Kinase, Winship Cancer Institute; Ad-OC-hsvTK/valacyclovir, Winship Cancer Institute
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D02KBE
 Compound Name Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy Phase 1 [14]
Synonyms
Thymidine kinase-expressing adenovirus and ganciclovir suicide genetherapy (cancer); Ad5-SSTR/TK-RGD; Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy (cancer), University of Alabama
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0FY1W
 Compound Name Rilapladib Phase 1 [15]
MOA Inhibitor
External Link
CID: 9918381
TTD: D05GZD
DrugBank: DB05119
 Compound Name Sitimagene ceradenovec Discontinued in Phase 3 [16]
Synonyms
Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0W8RX
 Compound Name 6-Hydroxypropylthymine Investigative [7]
Synonyms
6-(3-hydroxypropyl)thymine; 6-(3-hydroxypropyl)-5-methylpyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 6-(3-hydroxypropyl)-5-methyl-; 156569-47-0; AC1L1CEO; SCHEMBL4315838; CHEBI:43299; CTK8A4001; DB04139
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 1865
TTD: D00CEO
DrugBank: DB04139
 Compound Name 3-(2-propyn-1-yl)thymidine Investigative [17]
Synonyms
3-Propargylthymidine; SCHEMBL1619074; CHEMBL524872
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11323459
TTD: D01CUJ
 Compound Name ITdU Investigative [15]
Synonyms
3-Hydroxyandrost-5-en-17-one; Diandron, 17-Hormoforin; A-hydroxy-5-androsten-17-one; Spectrum_000661; SpecPlus_000094; Androst-5-en-17-one, 3-hydroxy-, (3.beta.)-; Spectrum3_000116; Spectrum5_000130; Spectrum4_001395; Spectrum2_000359; AC1L18FD; KBioSS_001141; KBioGR_001750; CHEMBL31399; DivK1c_006190; SPBio_000457; SCHEMBL9969169; KBio1_001134; KBio3_000872; KBio2_006277; KBio2_003709; KBio2_001141; CHEBI:95212; MolPort-003-891-893; ALBB-023670; CCG-38634; Androst-5-en-17-one, 3-hydroxy-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 76
TTD: D01VKE
 Compound Name 5-Iodo-2'-Deoxyuridine-5'-Monophosphate Investigative [7]
Synonyms
AC1L52UF; [(2R,3S)-3-hydroxy-5-(5-iodo-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 449489
TTD: D04GXW
DrugBank: DB02324
 Compound Name 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine Investigative [18]
Synonyms
CHEMBL219905
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16098875
TTD: D07GKK
 Compound Name (South)-Methanocarba-Thymidine Investigative [7]
Synonyms
south-methanocarbathymidine; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hex-1-yl]-5-methylpyrimidine-2,4(1H,3H)-dione; SCT; 1-[(1S,3S,4R,5S)-3-hydroxy-4-(hydroxymethyl)bicyclo[3.1.0]hexan-1-yl]thymine; (1S,3S,4R,5S)-3-hydroxy-4-hydroxymethyl-1-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)bicyclo[3.1.0]hexane; [(S)-Methanocarba-T]; South-Methanocarba-thymine; AC1L9L1U; 2'-exo-Methanocarbathymidine; CHEBI:45586; XRMLXZVSFIBRRJ-PEFMBERDSA-N; DB02921
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 447628
TTD: D07OOW
DrugBank: DB02921
 Compound Name 6-(Dihydroxy-Isobutyl)-Thymine Investigative [7]
Synonyms
DHBT; 6-(1,3-dihydroxyisobutyl)thymine; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methylpyrimidine-2,4(1H,3H)-dione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-2,4(1h,3h)-pyrimidinedione; 6-[3-hydroxy-2-(hydroxymethyl)propyl]thymine; CCV; AC1L1CE0; CTK8A1595; CHEBI:41485; DB02500; 6-[3-hydroxy-2-(hydroxymethyl)propyl]-5-methyl-1H-pyrimidine-2,4-dione
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 1855
TTD: D08AOD
DrugBank: DB02500
 Compound Name 5-propyl-2'-deoxyuridine Investigative [19]
Synonyms
27826-74-0; CHEMBL221982; 5-Propyldeoxyuridine; 2'-Deoxy-5-propyluridine; 5-Propyl-dUrd; 5-Propyl-2'-desoxyuridine; AC1L4N4W; 2'-deoxy-5-n-propyluridine; Uridine,2'-deoxy-5-propyl-; Uridine, 2'-deoxy-5-propyl-; SCHEMBL2396529; CTK4G0305; DTXSID30182141; MBERTAKFBYOAHR-IVZWLZJFSA-N; BDBM50375778; 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidine-2,4-dione
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 20000 nM
External Link
CID: 160155
TTD: D0C7YS
 Compound Name L-5-(bromovinyl)deoxyuridine Investigative [19]
Synonyms
CHEMBL261850; SCHEMBL4314668; BDBM50375781
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 25323027
TTD: D0D7FB
 Compound Name 9-(4-Hydroxybutyl)-N2-Phenylguanine Investigative [7]
Synonyms
HBPG; CHEMBL406254; BPG; 6H-Purin-6-one, 1,9-dihydro-9-(4-hydroxybutyl)-2-(phenylamino)-; 161363-19-5; 1QHI; AC1L9LM8; SCHEMBL1506775; SCHEMBL17485742; CTK0A9784; BDBM21866; DTXSID00332272; AKOS030558959; N2-Phenyl-9-(4-hydroxybutyl) guanine; DB02495; 9-(4-Hydroxybuthyl)-N2-Phenylguanine; 2-anilino-9-(4-hydroxybutyl)-1H-purin-6-one; 2-anilino-9-(4-hydroxybutyl)-3H-purin-6-one; 9-(4-hydroxybutyl)-2-(phenylamino)-1,9-dihydro-6H-purin-6-one
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 50 nM
External Link
CID: 135415618
TTD: D0G5VO
DrugBank: DB02495
 Compound Name L-5-iodo-2'-deoxyuridine Investigative [19]
Synonyms
CHEMBL408518; URIDINE, 2'-DEOXY-5-IODO-; AC1LAEAG; SCHEMBL51859; XQFRJNBWHJMXHO-XVMARJQXSA-N; ZINC5223557; BDBM50375780; FT-0620507; 5-Iodo-1-(2-deoxy-alpha-D-ribofuranosyl)uracil
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 512326
TTD: D0HO0W
 Compound Name 3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine Investigative [20]
Synonyms
3'-(1,2,3-Triazol)dT; 3'-Deoxy-3'-(1,2,3-triazol-1-yl)thymidine; 122370-58-5; CHEMBL1092729; Thymidine,3'-deoxy-3'-(1H-1,2,3-triazol-1-yl)- (9CI); AC1L9Q42; SCHEMBL9965127; CTK4B3087; DTXSID60153586; BDBM50314847; 3'-(1H-1,2,3-Triazol-1-yl)-3'-deoxythymidine; 3''-(1,2,3-Triazol-1-yl)-3''-deoxy-beta-D-thymidine; 1-[(2R,4S,5S)-5-(hydroxymethyl)-4-(triazol-1-yl)tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
    Click to Show/Hide
MOA Inhibitor
Activity IC50 >= 500000 nM
External Link
CID: 452142
TTD: D0O7GD
 Compound Name BVDU-MP Investigative [21]
Synonyms
SCHEMBL4287705
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 46936977
TTD: D0PC2Y
 Compound Name 9-Hydroxypropyladenine, S-Isomer Investigative [7]
Synonyms
(S)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; 14047-27-9; (S)-9-(2-Hydroxypropyl)adenine; (2S)-1-(6-amino-9H-purin-9-yl)propan-2-ol; AC1L9HLO; Tenofovir Related Compound 9; S-9-(2-hydroxypropyl)adenine; SCHEMBL5810639; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaS)-; CTK8C2128; DTXSID60332177; MolPort-003-848-032; ZINC2046907; ANW-67863; 6827AA; DB03000; SC-43410; AK-82057; AJ-33425; KB-106920; TX-015702; (2S)-1-(6-aminopurin-9-yl)propan-2-ol; AX8236781; FT-0696938; ST24035731
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 445210
TTD: D0R0EI
DrugBank: DB03000
 Compound Name 2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine Investigative [19]
MOA Inhibitor
External Link
CID: 448110
TTD: D0S4SQ
 Compound Name 5-Bromothienyldeoxyuridine Investigative [7]
Synonyms
CHEMBL1231486; 5-(5-Bromo-2-thienyl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-2'-deoxyuridine; BTD; 134333-70-3; BTDU; Uridine,5-(5-bromo-2-thienyl)-2'-deoxy-; AC1L9K0Y; SCHEMBL1636648; CHEMBL358374; CTK4B9107; BDBM50054768; DB03804; 5-(5-Bromothien-2-yl)-2'-deoxyuridine-; 5-(5-bromothiophen-2-yl)-2'-deoxyuridine; 5-(5-Bromothien-2-yl)-1- (.beta.-D-2-deoxyribofuranos-1-yl)uracil; 5-(5-Bromo-thiophen-2-yl)-1-(4-hydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidine-2,4-dione
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 446725
TTD: D0ST5A
DrugBank: DB03804
 Compound Name 1-[7-(triphenylmethoxy)heptyl]thymine Investigative [18]
Synonyms
CHEMBL219367; 921587-94-2; CTK3G1843; DTXSID20582671; BDBM50200997; 5-Methyl-1-[7-(triphenylmethoxy)heptyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[7-(triphenylmethoxy)heptyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16098874
TTD: D0W8AD
 Compound Name 9-Hydroxypropyladenine, R-Isomer Investigative [7]
Synonyms
14047-28-0; (R)-9-(2-Hydroxypropyl)adenine; (R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; (R)-(+)-9-(2-HYDROXYPROPYL)ADENINE; (2R)-1-(6-aminopurin-9-yl)propan-2-ol; UNII-43H6SBP55W; (R)-9-(2-hydroxypropyl) adenine; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, (alphaR)-; 43H6SBP55W; AK-59150; (2R)-1-(6-Amino-9H-purin-9-yl)propan-2-ol; ARP; W-201193; 9-(2-Hydroxypropyl)adenine, (R)-; PubChem9984; R-9-(2-hydroxypropyl)adenine [WHO-DD]; AC1L9HLR; 9H-Purine-9-ethanol, 6-amino-alpha-methyl-, D-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 445211
TTD: D0X1HX
DrugBank: DB02765
 Compound Name Edoxudine Investigative [19]
Synonyms
5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3-dihydropyrimidine-2,4-d ione; ORF-15817; RWJ-15817; Edurid (Salt/Mix); 1-(2-deoxypentofuranosyl)-5-ethylpyrimidine-2,4(1h,3h)-dione; AC1L1CAR; .beta.-5-Ethyldeoxyuridine; TimTec1_004024; SCHEMBL65580; MLS001360450; AC1Q69H9; 5-ethyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione; .beta.-5-Ethyl-2'-deoxyuridine; XACKNLSZYYIACO-UHFFFAOYSA-N; HMS3056J10; HMS3369L22; HMS1545G20; EDU; AKOS024282522; 5-Ethyl-2'-deoxyuridine; MCULE-3445830855; ST056929
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 66377
TTD: D0Y4MD
DrugBank: DB13421
 Compound Name N2-(3-trifluoromethylphenyl)guanine Investigative [19]
MOA Inhibitor
External Link
CID: 135435057
TTD: D0YJ5W
 Compound Name 2'-Deoxyuridine Investigative [6]
Synonyms
951-78-0; deoxyuridine; Uracil deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione; 2-Deoxyuridine; Deoxyribose uracil; 2'-Desoxyuridine; UNII-W78I7AY22C; CCRIS 2832; dURD; EINECS 213-455-7; BRN 0024433; 1-(2-Deoxy-beta-D-ribofuranosyl)uracil; W78I7AY22C; CHEBI:16450; 2 -Deoxyuridine; 1-(2-Deoxy-beta-D-erythro-pentofuranoxyl)uracil; MFCD00006527; AK-54658; 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-beta-D-ribofuranosyl)-; NSC 23615
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 13712
TTD: D00CVB
DrugBank: DB02256
 Compound Name 1-[5-(triphenylmethoxy)pentyl]thymine Investigative [18]
Synonyms
CHEMBL216997; 921587-92-0; CTK3G1845; DTXSID10582665; BDBM50201001; 5-Methyl-1-[5-(triphenylmethoxy)pentyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[5-(triphenylmethoxy)pentyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 16098859
TTD: D00KWL
 Compound Name Deoxythymidine Investigative [7]
Synonyms
Thymidine; 50-89-5; 2'-Deoxythymidine; Beta-Thymidine; 5-Methyldeoxyuridine; Thymidin; DThyd; 5-Methyl-2'-deoxyuridine; Thymine-2-deoxyriboside; Thyminedeoxyriboside; Thymine-2-desoxyriboside; 5-Methyldeoxyurindine; dThd; Uridine, 2'-deoxy-5-methyl-; Thymine deoxyriboside; 1-((2R,4S,5R)-4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione; dT; UNII-VC2W18DGKR; Deoxyribothymidine; AI3-52267; 2'-thymidine; beta-D-Ribofuranoside, thymine-1 2-deoxy-; CCRIS 1283; CHEBI:17748
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 26 nM
External Link
CID: 5789
TTD: D01GLG
DrugBank: DB04485
 Compound Name 1-[6-(triphenylmethoxy)hexyl]thymine Investigative [18]
Synonyms
CHEMBL216998; 921587-93-1; CTK3G1844; DTXSID00658828; BDBM50200990; 5-Methyl-1-[6-(triphenylmethoxy)hexyl]pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione, 5-methyl-1-[6-(triphenylmethoxy)hexyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44418795
TTD: D02CCD
 Compound Name P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate Investigative [11]
Synonyms
CHEMBL1236157; T5A; 3tmk; 1mrn; 4TMK; AC1L9KL2; BDBM50366828; DB03280; adenosine 5'-(hexahydrogen pentaphosphate), P"" 5'-ester with thymidine; 103137-88-8; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [hydroxy-[hydroxy-[hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphoryl]oxyphosphoryl]oxyphosphoryl] hydrogen phosphate
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 447202
TTD: D04BBF
DrugBank: DB03280
 Compound Name 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine Investigative [18]
Synonyms
CHEMBL101135; 5-methyl-1-[(Z)-4-trityloxybut-2-enyl]pyrimidine-2,4-dione; AC1O54TL; 5-Methyl-1-(4-trityloxy-but-2-enyl)-1H-pyrimidine-2,4-dione; SCHEMBL19196301; BDBM50118490; 5-Methyl-1-[(2Z)-4-(trityloxy)but-2-enyl]pyrimidine-2,4(1H,3H)-dione
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 180 nM
External Link
CID: 6477686
TTD: D0I6UV
 Compound Name Thymidine-5'-Phosphate Investigative [7]
Synonyms
Thymidine 5'-monophosphate; dTMP(-); thymidine 5'-phosphate(1-); CHEBI:46960; thymidine 5'-(hydrogen phosphate)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9700
TTD: D0ZH0I
DrugBank: DB01643
 Compound Name 2'-deoxythymidine triphosphate Investigative [7]
Synonyms
Thymidine-5'-triphosphate; dTTP; thymidine 5'-triphosphate; Deoxy-TTP; Deoxythymidine 5'-triphosphate; 5'-TTP; thymidine 5'-(tetrahydrogen triphosphate); TTP (nucleotide); thymidine triphosphate; pppdT; TTP; UNII-QOP4K539MU; 5-Methyl-dUTP; dThd5'PPP; CHEBI:18077; EINECS 206-669-7; QOP4K539MU; CHEMBL363559; 2'-Deoxythymidine 5'-triphosphate; 18423-43-3; [hydroxy-[[(2R,3S,5R)-3-hydroxy-5-(5-methyl-2,4-dioxo-pyrimidin-1-yl)tetrahydrofuran-2-yl]methoxy]phosphoryl] phosphono hydrogen phosphate; DEOXYTHYMIDINE_TRIPHOSPHATE
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 64968
TTD: D09WYY
DrugBank: DB02452
2C12: Liver cancer 49 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name 90Y-loaded resin microspheres Approved [22]
External Link
TTD: DGWE36
 Compound Name Thymalfasin Phase 2 [23]
Synonyms
Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1
    Click to Show/Hide
External Link
CID: 16130571
TTD: D0I5KX
 Compound Name Ferumoxides Approved [24]
Synonyms
AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric
    Click to Show/Hide
External Link
CID: 6432052
TTD: D08QAC
DrugBank: DB06215
 Compound Name DTI-015 Approved [25]
Synonyms
Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics
    Click to Show/Hide
External Link
CID: 2578
TTD: D01OXI
DrugBank: DB00262
 Compound Name Nofazinlimab Phase 3 [26]
Synonyms
CS1003; EQ176
    Click to Show/Hide
External Link
TTD: DX9GT7
 Compound Name PV-10 Phase 3 [27]
Synonyms
632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium
    Click to Show/Hide
External Link
CID: 69438
TTD: D0L2VT
 Compound Name Brivanib Phase 3 [28]
Synonyms
649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol
    Click to Show/Hide
External Link
CID: 11234052
TTD: D0HS5V
DrugBank: DB11958
 Compound Name JX-594 Phase 3 [29]
Synonyms
Pexastimogene devacirepvec
    Click to Show/Hide
External Link
TTD: D0HB0V
 Compound Name ABH001 Phase 3 [30]
External Link
TTD: D05LPP
 Compound Name MTC-DOX Phase 2/3 [31]
Synonyms
MTC-doxorubicin
    Click to Show/Hide
External Link
TTD: D0W9AI
 Compound Name KD018 Phase 2 [32]
External Link
TTD: D0NB9T
 Compound Name Doxorubicin-eluting beads Phase 2 [33]
Synonyms
DC Bead (TN)
    Click to Show/Hide
External Link
TTD: D0M5CD
 Compound Name 32-P BioSilicon Phase 2 [34]
Synonyms
BrachySil
    Click to Show/Hide
External Link
TTD: D0M1YS
 Compound Name Cixutumumab Phase 2 [35]
Synonyms
LY3012217
    Click to Show/Hide
External Link
TTD: D0E5DP
 Compound Name [131I]-Metuximab Phase 2 [36]
External Link
TTD: D0E5BW
 Compound Name Darinaparsin Phase 2 [37]
Synonyms
ZIO-101
    Click to Show/Hide
External Link
CID: 11683005
TTD: D03ZME
DrugBank: DB06179
 Compound Name Tigatuzumab Phase 2 [38]
External Link
TTD: D03LTO
 Compound Name CMC-001 Phase 2 [39]
Synonyms
Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast
    Click to Show/Hide
External Link
TTD: D00WMJ
 Compound Name OBP-301 Phase 1/2 [40]
External Link
TTD: D0D8ZK
 Compound Name MBO7133 Phase 1/2 [41]
External Link
TTD: D0C3MW
 Compound Name INCB62079 Phase 1/2 [27]
External Link
TTD: D0BE8H
 Compound Name NV-1020 Phase 1/2 [42]
External Link
TTD: D0B6EA
 Compound Name DCVax-Liver Phase 1/2 [43]
Synonyms
Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D00ESH
 Compound Name SRF388 Phase 1 [44]
External Link
TTD: DLY89F
 Compound Name ET140202 Phase 1 [45]
External Link
TTD: D4K2OF
 Compound Name ADP-A2AFP Phase 1 [46]
External Link
TTD: D31ORV
 Compound Name SM04755 Phase 1 [47]
External Link
TTD: D0P5XM
 Compound Name Anti-CEA CAR-T therapy Phase 1 [27]
External Link
TTD: D0OP1L
 Compound Name PI-166 Phase 1 [48]
External Link
TTD: D0J2YR
 Compound Name CRS-100 Phase 1 [49]
External Link
TTD: D0B4DL
 Compound Name Autologous ET1402L1-CART cells Phase 1 [50]
External Link
TTD: D09TGO
 Compound Name Anti-CD133-CAR vector-transduced T cells Phase 1 [51]
External Link
TTD: D09HRH
 Compound Name MRX34 Phase 1 [52]
External Link
TTD: D08SJY
 Compound Name ALN-VSP Phase 1 [53]
External Link
TTD: D08JMI
 Compound Name EPCAM-targeted CAR-T cells Clinical trial [54]
External Link
TTD: D0T8DD
 Compound Name ADI Discontinued in Phase 3 [55]
Synonyms
Arginine deiminase
    Click to Show/Hide
External Link
CID: 46906074
TTD: D0O4EV
 Compound Name GN-1140 Discontinued in Phase 2 [56]
External Link
TTD: D0V4CL
 Compound Name OGT-719 Discontinued in Phase 2 [57]
Synonyms
OGS-719
    Click to Show/Hide
External Link
CID: 9838997
TTD: D0C2CH
 Compound Name AFP-Scan Discontinued in Phase 2 [58]
External Link
TTD: D08CCC
 Compound Name SR1078 Preclinical [59]
Synonyms
1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2
    Click to Show/Hide
External Link
CID: 17980288
TTD: D9D6QN
 Compound Name Occlusin Preclinical [60]
Synonyms
Occlusin 50 Injection; Occlusin 500 injection
    Click to Show/Hide
External Link
TTD: D00INM
 Compound Name HRC-201 Terminated [61]
Synonyms
Hemoglobin-imaging conjugate (HepSelect), Hemosol
    Click to Show/Hide
External Link
TTD: D09ZCH
 Compound Name 1,2,3,4,5,6-hexabromocyclohexane Investigative [62]
Synonyms
1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694
    Click to Show/Hide
External Link
CID: 74603
TTD: DLW69V
 Compound Name STP-322 Investigative [63]
Synonyms
Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics
    Click to Show/Hide
External Link
TTD: D0R8KF
 Compound Name AMB-8LK Investigative [63]
Synonyms
Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma
    Click to Show/Hide
External Link
TTD: D0P2MD
 Compound Name MiR-34a mimics Investigative [63]
Synonyms
MiR-34a mimics (liver cancer)
    Click to Show/Hide
External Link
TTD: D0M9TD
 Compound Name P53 fusion protein Investigative [63]
Synonyms
P53 fusion protein (pancreatic/liver cancer)
    Click to Show/Hide
External Link
TTD: D06WLG
 Compound Name OP-05 Investigative [63]
Synonyms
OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon
    Click to Show/Hide
External Link
TTD: D02OIP
 Compound Name GR-DD1 Investigative [63]
Synonyms
Cytotoxin (hepatic metastasis), ERYtech
    Click to Show/Hide
External Link
TTD: D00QFV
References
Ref 1 Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression. Oncogene. 2021 Jan;40(1):28-45. doi: 10.1038/s41388-020-01498-3. Epub 2020 Oct 13.
Ref 2 Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018 Mar;20(3):285-295. doi: 10.1038/s41556-018-0045-z. Epub 2018 Feb 23.
Ref 3 DNA methyltransferase inhibitors: an updated patent review (2012-2015). Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. doi: 10.1080/13543776.2016.1209488. Epub 2016 Jul 18.
Ref 4 Inhibitors of protein tyrosine phosphatases. US9217012.
Ref 5 US patent application no. 6,204,055, Antisense inhibition of Fas mediated signaling.
Ref 6 Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9. doi: 10.1021/jm00348a007.
Ref 7 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Ref 8 Company report (Takara Bio)
Ref 9 Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54. doi: 10.1124/mol.61.2.249.
Ref 10 Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8.
Ref 11 DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. doi: 10.1093/nar/gkq1126. Epub 2010 Nov 8.
Ref 12 Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7. doi: 10.1097/00001622-200109000-00008.
Ref 13 Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41. doi: 10.1089/10430340360535788.
Ref 14 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 15 Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1)(Pt 1):15-22. doi: 10.1042/bj3340015.
Ref 16 Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol. 2010 Nov;6(11):1691-710. doi: 10.2217/fon.10.134.
Ref 17 Synthesis, in vitro, and in silico evaluation of organometallic technetium and rhenium thymidine complexes with retained substrate activity toward human thymidine kinase type 1. J Med Chem. 2008 Nov 13;51(21):6689-98. doi: 10.1021/jm800530p. Epub 2008 Oct 7.
Ref 18 N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73. doi: 10.1021/jm0610550.
Ref 19 Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate analogs and acyclonucleosides. Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34. doi: 10.1128/AAC.01284-06. Epub 2007 Apr 16.
Ref 20 3'-[4-Aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidine analogues as potent and selective inhibitors of human mitochondrial thymidine kinase. J Med Chem. 2010 Apr 8;53(7):2902-12. doi: 10.1021/jm901532h.
Ref 21 Crystal structure of varicella zoster virus thymidine kinase. J Biol Chem. 2003 Jul 4;278(27):24680-7. doi: 10.1074/jbc.M302025200. Epub 2003 Apr 9.
Ref 22 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
Ref 23 ClinicalTrials.gov (NCT01031966) A Pilot Study to Evaluate ZADAXIN's (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine. U.S. National Institutes of Health.
Ref 24 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 25 Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62.
Ref 26 ClinicalTrials.gov (NCT04194775) A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC). U.S.National Institutes of Health.
Ref 27 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5671).
Ref 29 ClinicalTrials.gov (NCT02017678) Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin. U.S. National Institutes of Health.
Ref 30 ClinicalTrials.gov (NCT01749306) A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing. U.S. National Institutes ofHealth.
Ref 31 ClinicalTrials.gov (NCT00034333) Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer. U.S. National Institutes of Health.
Ref 32 ClinicalTrials.gov (NCT00730158) A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026037)
Ref 34 PRODUCTS: BrachySil. Psivida corp
Ref 35 ClinicalTrials.gov (NCT01232452) A Study in Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 36 ClinicalTrials.gov (NCT00819650) A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection. U.S. National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT00421213) Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers. U.S. National Institutes of Health.
Ref 38 ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
Ref 39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021589)
Ref 40 ClinicalTrials.gov (NCT02293850) Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health.
Ref 41 Clinical pipeline report, company report or official report of Metabasis Therapeutics (2006).
Ref 42 ClinicalTrials.gov (NCT00149396) Safety and Efficacy of a Genetically Engineered Herpes Simplex Virus NV1020 to Treat Colorectal Cancer Metastatic to Liver. U.S. National Institutes of Health.
Ref 43 ClinicalTrials.gov (NCT01882946) Safety and Efficacy Study of DCVax-Direct in Solid Tumors. U.S. National Institutes of Health.
Ref 44 ClinicalTrials.gov (NCT04374877) Study of SRF388 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 45 ClinicalTrials.gov (NCT03965546) Clinical Study of ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Advanced Liver Cancer. U.S.National Institutes of Health.
Ref 46 ClinicalTrials.gov (NCT03132792) A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFP????T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types. U.S.National Institutes of Health.
Ref 47 ClinicalTrials.gov (NCT02191761) Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer. U.S. National Institutes of Health.
Ref 48 Clinical pipeline report, company report or official report of Progen.
Ref 49 ClinicalTrials.gov (NCT00327652) Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases. U.S. National Institutes of Health.
Ref 50 ClinicalTrials.gov (NCT03349255) Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Ref 51 ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Ref 52 ClinicalTrials.gov (NCT01829971) A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection. U.S. National Institutes of Health.
Ref 53 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
Ref 54 ClinicalTrials.gov (NCT02729493) Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer
Ref 55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003116)
Ref 56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015394)
Ref 57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009854)
Ref 58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008092)
Ref 59 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
Ref 60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018427)
Ref 61 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020214)
Ref 62 Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr. 2007 Nov;137(11):2366-70.
Ref 63 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.